# The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma

> **NCT00270101** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 156 (actual)

## Conditions studied

- Anemia
- Multiple Myeloma

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00270101
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-01
- **Primary completion:** —
- **Final completion:** 1996-09
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270101, "The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00270101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*